New Horizon Health Limited

6606

KYG6485S1021

Medical Equipment, Supplies & Distribution

Delayed Hong Kong S.E. Other stock markets 04:08:30 2024-03-27 am EDT			5-day change	1st Jan Change
14.14 ^HKD	-19.75%		-.--%	-38.92%

Apr. 08	New Horizon Health Limited Announces Board Appointments	CI
Mar. 28	New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023	CI

New Horizon Health Limited(SEHK:6606) added to S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about New Horizon Health Limited

New Horizon Health Limited Announces Board Appointments	Apr. 08	CI
New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023	Mar. 28	CI
New Horizon Health Forecasts Up to 168% Rise in 2023 Revenue	Jan. 22	MT
New Horizon Health Limited Provides Group Earnings Guidance for the Year Ended December 31, 2023	Jan. 22	CI
New Horizon Health Swings to Profit in H1 as Revenue Soars 265%	23-08-22	MT
New Horizon Health Limited commences an Equity Buyback Plan for 45,759,199 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023.	23-08-22	CI
New Horizon Health Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
New Horizon Health Rejects Short Seller's Allegations	23-08-17	MT
New Horizon Health Forecasts Swing to Profit in H1; Shares Plunge 9%	23-08-07	MT
New Horizon Health Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023	23-08-04	CI
New Horizon Health Plans Up to HK$500 Million Share Repurchase	23-07-16	MT
New Horizon Health Sees Up to 271% Increase in H1 Revenue	23-07-10	MT
New Horizon Health Limited Provides Group Earnings Guidance for the Six Months Ended June 30, 2023	23-07-10	CI
New Horizon Health Grants Share Options, RSUs to Various Directors, Employees	23-06-12	MT
New Horizon Health Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-13	CI
New Horizon Health Chief Scientific Officer to Sell 6.41% Stake; Shares Fall 4%	23-01-17	MT
New Horizon Health Expects Up to 268% Boost in FY22 Revenue	23-01-12	MT
New Horizon Health Limited Provides Group Earnings Guidance for the Year Ended December 31, 2022	23-01-12	CI
New Horizon Health Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-19	CI
UBS Adjusts New Horizon Health's Price Target to HK$51 From HK$47, Keeps at Buy	22-07-20	MT
New Horizon Health Limited Announces Address Changes	22-07-15	CI
New Horizon Health Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022	22-07-15	CI
New Horizon Health Gets New Chairman in Management Shake-up	22-06-21	MT
New Horizon Health Limited Announces Board Changes	22-06-20	CI
New Horizon Health Partners with Prenetics in Hong Kong to Launch ColoClear, a Non-Invasive Stool DNA Test to Detect Colon Cancer	22-05-23	CI

Chart New Horizon Health Limited

Duration

Period

More charts

New Horizon Health Ltd is a China-based investment holding company principally engaged in the research, development, clinical development, test operation and commercialization of screening products for colorectal cancer, gastric cancer and cervical cancer. The Company distributes its ColoClear, Pupu tube and other products to customers through its own network, contracted sales organisations (CSOs) and Internet sales or e-platform operated by healthcare clinics. The Companyâs Youyou Tube (a stool-based self-checking gastric cancer screening test) and CerviClear (a non-invasive urine cervical cancer home screening test) are under development.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-15 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for New Horizon Health Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.06 CNY

Average target price

32.48 CNY

Spread / Average Target

+148.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
NEW HORIZON HEALTH LIMITED	-38.92%	811M
BIOMÉRIEUX	-1.09%	12.59B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-12.53%	7.42B
DIASORIN S.P.A.	+0.45%	5.35B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.37%	4.51B
LANTHEUS HOLDINGS, INC.	+5.16%	4.47B
10X GENOMICS, INC.	-51.93%	3.21B
ANDON HEALTH CO., LTD.	+11.34%	2.71B
VITROLIFE AB	-19.05%	1.96B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.07%	1.73B

Diagnostic & Testing Substances